A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer

Hepato-Gastroenterology

Volumn 50, Issue 50, 2003, Pages 567-570

  Kurtz, Jean Emmanuel ^a   Négrier, Sylvie ^b   Husseini, Fares ^e   Limacher, Jean Marc ^a   Borel, Christian ^c   Wagner, Jean Philippe ^d   Prévot, Gilles ^e   Bergerat, Jean Pierre ^a   Dufour, Patrick ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b CENTRE LÉON BÉRARD   (France)

^c CENTRE PAUL STRAUSS   (France)

^d Clinique de l'Orangerie Strasbourg   (France)

^e NONE

Author keywords

Chemotherapy; Docetaxel; Irinotecan; Pancreatic cancer

Indexed keywords

ANTIEMETIC AGENT; ATROPINE; DOCETAXEL; HEMOPOIETIC GROWTH FACTOR; IRINOTECAN; PREDNISOLONE; SEROTONIN 3 ANTAGONIST;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANXIETY DISORDER; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; LIVER TOXICITY; METASTASIS; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CAMPTOTHECIN; DIARRHEA; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; PACLITAXEL; PANCREATIC NEOPLASMS; TAXOIDS;

EID: 0037350609     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Wagener DJ, Verdonk HE, Dirix LY, et al: Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 1995; 6(2):129-132.
2. Sakata Y, Shimada Y, Yoshino M, et al: A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 Study Group on Gastrointestinal Cancer. Gan To Kagaku Ryoho 1994; 21(7):1039-1046.
3. Klapdor R, Fenner C: Irinotecan (Campto R): efficacy as third/forth line therapy in advanced pancreatic cancer. Anticancer Res 2000; 20(6D):5209-5212.
4. Kozuch P, Grossbard ML, Barzdins A, et al: Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 2001; 6(6):488-495.
5. Rougier P, Adenis A, Ducreux M, et al: A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 2000; 36(8):1016-1025.
6. Okada S, Sakata Y, Matsuno S, et al: Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan. Br J Cancer 1999; 80(3-4):438-443.
7. Androulakis N, Kourousis C, Dimopoulos MA, et al: Treatment of pancreatic cancer with docetaxel and granulocyte colony- stimulating factor: a multicenter phase II study. J Clin Oncol 1999; 17(6):1779-1785.
8. Cascinu S, Gasparini G, Catalano V, et al: A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol 1999; 10(11):1377-1379.
9. Couteau C, Risse ML, Ducreux M, et al: Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors. J Clin Oncol 2000; 18(20):3545-3552.
10. Heinemann V: Gemcitabine: progress in the treatment of pancreatic cancer. Oncology 2001; 60(1):8-18.
11. Burris H, Storniolo AM: Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 1997; 33(Suppl 1):S18-22.
12. Kurtz JE, Trillet-Lenoir V, Bugat R, et al: Compassionate use of gemcitabine in advanced pancreatic cancer: a French multicentric study. Bull Cancer 1999; 86(2):202-206.
13. Burris HA, 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15(6):2403-2413.
14. Kurtz JE, Kohser F, Negrier S, et al: Gemcitabine and protracted 5-FU for advanced pancreatic cancer. A phase II study. Hepatogastroenterology 2000; 47(35):1450-1453.
15. Adjei AA, Klein CE, Kastrissios H, et al: Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. J Clin Oncol 2000; 18(5):1116-1123.
16. Rocha Lima CMS, Savarese D, Bruckner H, et al: Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002; 20(5):1182-1191.
17. Rocha Lima CM, Urbanic JJ, Sherman CA, Brescia FJ, Green MR: Docetaxel followed by gemcitabine and irinotecan in solid tumors. Oncology (Huntingt) 2001; 15(1 Suppl 1):37-45.
18. Rothenberg ML, Moore MJ, Cripps MC, et al: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7(4):347-353.